Regression of orbital and choroidal metastases from melanoma after treatment with vemurafenib.
University of Arkansas for Medical Sciences, Little Rock, Ark. Electronic address: Engo@uams.edu.
Ellen
E
Ngo
University of Arkansas for Medical Sciences, Little Rock, Ark.
Laura F
LF
Hutchins
University of Arkansas for Medical Sciences, Little Rock, Ark.
Jerad M
JM
Gardner
University of Arkansas for Medical Sciences, Little Rock, Ark.
Sami H
SH
Uwaydat
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002830:Choroid Neoplasms / Q000188:drug therapy* / Q000556:secondary; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D008279:Magnetic Resonance Imaging; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000556:secondary; D008875:Middle Aged; D009918:Orbital Neoplasms / Q000188:drug therapy* / Q000556:secondary; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology; D013449:Sulfonamides / Q000627:therapeutic use*; D000077484:Vemurafenib
D000970:Antineoplastic Agents; D007211:Indoles; D013449:Sulfonamides; D000077484:Vemurafenib; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf